If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Silvia Damian is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 0 Similar Profiles
letrozole Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Anthracyclines Medicine & Life Sciences
Safety Medicine & Life Sciences
Salivary Glands Medicine & Life Sciences
L-Lactate Dehydrogenase Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2016 2019

Open Access
L-Lactate Dehydrogenase
Monoclonal Antibodies
CD274 Antigen
Area Under Curve

Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study

Mariani, G., Galli, G., Cavalieri, S., Valagussa, P., Bianchi, G. V., Capri, G., Cresta, S., Ferrari, L., Damian, S., Duca, M., de Braud, F. & Moliterni, A., Mar 1 2019, In : Breast Journal. 25, 2, p. 237-242 6 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Drug Therapy

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Schöffski, P., Cresta, S., Mayer, I. A., Wildiers, H., Damian, S., Gendreau, S., Rooney, I., Morrissey, K. M., Spoerke, J. M., Ng, V. W., Singel, S. M. & Winer, E., Sep 5 2018, In : Breast Cancer Research. 20, 1, p. 109

Research output: Contribution to journalArticle

Breast Neoplasms
Maximum Tolerated Dose
Phosphatidylinositol 3-Kinase

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study

Cohen, R. B., Delord, J-P., Doi, T., Piha-Paul, S. A., Liu, S. V., Gilbert, J., Algazi, A. P., Damian, S., Hong, R-L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J. & Keam, B., Feb 21 2018, In : American Journal of Clinical Oncology.

Research output: Contribution to journalArticle

Salivary Glands

Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1)

Drilon, A., Siena, S., Ou, S. H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., Doebele, R., Giannetta, L., Cerea, G., Marrapese, G., Schirru, M., Amatu, A., Bencardino, K., Palmeri, L., Sartore-Bianchi, A., Vanzulli, A. & 15 others, Cresta, S., Damian, S., Duca, M., Ardini, E., Li, G., Christiansen, J., Kowalski, K., Johnson, A. D., Patel, R., Luo, D., Chow-Maneval, E., Hornby, Z., Multani, P. S., Shaw, A. T. & De Braud, F. G., Apr 1 2017, In : Cancer Discovery. 7, 4, p. 400-409 10 p.

Research output: Contribution to journalArticle

Gene Fusion
Central Nervous System Diseases
Gene Targeting